Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
1 ratings / 3 average

Treatment Strategies

Giovannoni G, Cook S, Rammohan K et al.; CLARITY study group.

Barts and The London School of Medicine and Dentistry, London, UK.

 Lancet Neurol 2011;10:329–37.

Editor’s note: Establishing an orally available drug for the treatment of multiple sclerosis (MS) has recently received extra-ordinary efforts. An oral compound will facilitate treatment for affected patients and also promises a significant market for the promoting pharmaceutical company. Fingolimod and cladribine – two drugs recently tested in large Phase III clinical trial programs – competed to become the first oral treatment for relapsing–remitting MS. Fingolimod has been approved as first- and second-line therapy in the US and Europe, respectively; however, its competitor cladribine has been declined approval because of an inadequate safety profile and – as has been communicated by the company – will not be developed further.

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles